Revvity/$RVTY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revvity
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Ticker
$RVTY
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
11,000
ISIN
US7140461093
Website
Revvity Metrics
BasicAdvanced
$12B
43.57
$2.35
0.97
$0.28
0.27%
Price and volume
Market cap
$12B
Beta
0.97
52-week high
$128.29
52-week low
$87.70
Average daily volume
1.1M
Dividend rate
$0.28
Financial strength
Current ratio
3.576
Quick ratio
2.708
Long term debt to equity
43.539
Total debt to equity
43.542
Dividend payout ratio (TTM)
11.95%
Interest coverage (TTM)
4.54%
Profitability
EBITDA (TTM)
836.249
Gross margin (TTM)
56.25%
Net profit margin (TTM)
10.35%
Operating margin (TTM)
15.54%
Effective tax rate (TTM)
11.35%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
2.09%
Return on equity (TTM)
3.82%
Valuation
Price to earnings (TTM)
43.569
Price to revenue (TTM)
4.508
Price to book
1.61
Price to tangible book (TTM)
-8.46
Price to free cash flow (TTM)
23.823
Free cash flow yield (TTM)
4.20%
Free cash flow per share (TTM)
429.83%
Dividend yield (TTM)
0.27%
Forward dividend yield
0.27%
Growth
Revenue change (TTM)
1.62%
Earnings per share change (TTM)
95.55%
3-year revenue growth (CAGR)
-7.35%
10-year revenue growth (CAGR)
2.18%
3-year earnings per share growth (CAGR)
-27.46%
10-year earnings per share growth (CAGR)
4.97%
What the Analysts think about Revvity
Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Bulls say / Bears say
Revvity reported first-quarter earnings that exceeded Wall Street expectations, driven by steady demand from biotech clients for its medical equipment used in drug research. (reuters.com)
The company raised its 2025 revenue forecast to between $2.83 billion and $2.87 billion, up from a prior estimate of $2.80 billion to $2.85 billion, indicating confidence in its growth trajectory. (reuters.com)
Barclays upgraded Revvity's stock rating to 'Overweight' in October 2024, reflecting a positive outlook on the company's performance. (defenseworld.net)
Wells Fargo issued a pessimistic forecast for Revvity's stock price in April 2025, indicating potential concerns about the company's future performance. (americanbankingnews.com)
Barclays lowered its price target for Revvity to $110.00 in April 2025, suggesting a more cautious outlook on the stock. (techdows.com)
Insider selling activity, such as the sale of 15,170 shares by insider Joel S. Goldberg in January 2025, may signal potential concerns about the company's future prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Revvity Financial Performance
Revenues and expenses
Revvity Earnings Performance
Company profitability
Revvity News
AllArticlesVideos
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
Business Wire·2 months ago
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Benzinga·2 months ago
Revvity beats quarterly estimates on steady demand for medical equipment
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul18
Revvity
Dividend·Ex-dividend
Aug8
Revvity
Dividend·Payment
$0.07Per share
FAQs
What’s the current market cap for Revvity stock?
Revvity (RVTY) has a market cap of $12B as of July 11, 2025.
What is the P/E ratio for Revvity stock?
The price to earnings (P/E) ratio for Revvity (RVTY) stock is 43.57 as of July 11, 2025.
Does Revvity stock pay dividends?
Yes, the Revvity (RVTY) stock pays dividends to shareholders. As of July 11, 2025, the dividend rate is $0.28 and the yield is 0.27%. Revvity has a payout ratio of 11.95% on a trailing twelve-month basis.
When is the next Revvity dividend payment date?
The next Revvity (RVTY) dividend payment is scheduled for August 08, 2025.
What is the beta indicator for Revvity?
Revvity (RVTY) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.